Acute Myeloid Leukemia Pipeline 2025: Innovative Clinical Developments by 110+ Global Leaders - DelveInsight | Featuring Sellas Life Sciences, Stemline Therapeutics, Wugen, Schrodinger, MEI Pharma

Acute Myeloid Leukemia companies are TC BioPharm, Pacylex Pharmaceuticals, Vor Biopharma, Vincerx Pharma, Aptose Biosciences, Tr1X, Zhejiang ACEA Pharmaceutical, BeiGene, Seagen, Sanofi, Servier Bio-Innovation, Ryvu Therapeutics, Remix Therapeutics, Prelude Therapeutics, Precigen, PharmaEngine, Orca Biosystems, Immune System Key, MacroGenics, Sutro Biopharma, and others.
With Acute Myeloid Leukemia (AML) becoming increasingly prevalent worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is an urgent need for safer and more effective therapies. DelveInsight reports that over 110 pharmaceutical and biotech companies are actively developing more than 120 therapeutic candidates targeting AML. These therapies span multiple stages of clinical and preclinical development, highlighting significant innovation and commitment to addressing this major public health challenge.

The "Acute Myeloid Leukemia Pipeline Insight 2025" report by DelveInsight offers a comprehensive strategic analysis of the current R&D landscape. It examines clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives, making it an essential resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving AML therapeutics market and the breakthroughs shaping its future.

Explore the Cutting-Edge Landscape of Acute Myeloid Leukemia Drug Development [https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Key Takeaways from the Acute Myeloid Leukemia Pipeline Report

DelveInsight's report on the Acute Myeloid Leukemia (AML) pipeline highlights a highly active landscape, with over 110 companies developing more than 120 therapeutic candidates targeting AML.

Notable recent developments in 2025 include:

*
March 2025: CERo Therapeutics Holdings, Inc. received a favorable FDA review for its IND amendment related to Chemistry, Manufacturing, and Controls (CMC), enabling patient dosing and shortening production timelines by about one week.

*
February 2025: Moleculin Biotech, Inc. obtained FDA feedback on its IND amendment, allowing a reduction in Phase 3 trial size for the AnnAraC study, which tests Annamycin + Cytarabine in relapsed or refractory AML (R/R AML) patients.

*
February 2025: Kura Oncology and Kyowa Kirin reported positive topline results from KOMET-001, a Phase 2 registration-focused trial of ziftomenib, an oral menin inhibitor for R/R AML patients with NPM1 mutations.

*
February 2025: Auron Therapeutics advanced its KAT2A/B program, including the clinical candidate AUTX-703, and completed a $27 million Series B financing round to support further development.

*
January 2025: Medexus received FDA approval for GRAFAPEX Trademark , an alkylating agent combined with fludarabine, for use as a preparative regimen in alloHSCT for AML and MDS patients aged one year and older.

*
January 2025: PureTech Health was granted Fast Track designation by the FDA for LYT-200, an investigational AML therapy, accelerating development and review due to the urgent need for new treatments.

Leading companies involved in AML drug development include Sellas Life Sciences, Stemline Therapeutics, Wugen, Schrodinger, MEI Pharma, Vor Bio, TC BioPharm, Pacylex Pharmaceuticals, Vor Biopharma, Vincerx Pharma, Aptose Biosciences, Tr1X, Zhejiang ACEA Pharmaceutical, BeiGene, Seagen, Sanofi, Servier Bio-Innovation, Ryvu Therapeutics, Remix Therapeutics, Prelude Therapeutics, Precigen, PharmaEngine, Orca Biosystems, Immune System Key, MacroGenics, Sutro Biopharma, and others.

Promising AML pipeline candidates in various stages of development include Galinpepimut-S, Tagraxofusp, WU-NK-101, SGR-2921, Voruciclib, VADC45, and several more.

Acute Myeloid Leukemia Overview:

Acute Myeloid Leukemia (AML) is a fast-progressing blood cancer marked by the uncontrolled growth of immature myeloid cells (blasts) in the bone marrow and bloodstream. This abnormal proliferation interferes with normal blood cell development, impairing the production of red blood cells and platelets due to defective erythropoiesis and megakaryopoiesis. As a result, AML leads to rapid bone marrow failure, distinguishing it from slower-developing types of leukemia.

Download the Acute Myeloid Leukemia sample report to know in detail about the Acute Myeloid Leukemia treatment market [https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Acute Myeloid Leukemia Pipeline Analysis

The Acute Myeloid Leukemia pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Acute Myeloid Leukemia Market.

*
Categorizes Acute Myeloid Leukemia therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Acute Myeloid Leukemia drugs under development based on:

*
Stage of development

*
Acute Myeloid Leukemia Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Acute Myeloid Leukemia Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Acute Myeloid Leukemia Licensing agreements

*
Funding and investment activities supporting future Acute Myeloid Leukemia market advancement.

Unlock key insights into emerging Acute Myeloid Leukemia therapies and market strategies here: https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Acute Myeloid Leukemia Emerging Drugs

*
Galinpepimut-S: Sellas Life Sciences Group

Galinpepimut-S (GPS) is a novel immunotherapy designed to target the WT1 protein, a nuclear protein implicated in the development and progression of various cancers. While WT1 is essential for fetal kidney development, its expression is largely absent in normal adult tissues, making it an attractive target for cancer therapy.

GPS is being developed both as a monotherapy and in combination with other treatments for multiple cancer types. The therapy comprises four synthetic peptides, two of which carry single amino acid modifications that make them appear "non-self" to the immune system. This strategy helps reduce immune tolerance and enhances the immune system's ability to identify and eliminate cancer cells.

*
Tagraxofusp: Stemline Therapeutics, Inc.

TAGRAXOFUSP is a targeted cancer therapy engineered to act on the interleukin-3 receptor alpha (CD123), which is commonly expressed in several malignancies. The therapy combines recombinant human IL-3 with a modified diphtheria toxin (DT), in which the toxin's natural receptor-binding domain is replaced by IL-3. This design allows TAGRAXOFUSP to specifically bind to and enter cells expressing CD123.

Acute Myeloid Leukemia Pipeline Therapeutic Assessment

Acute Myeloid Leukemia Assessment by Product Type

- Mono

- Combination

- Mono/Combination

Acute Myeloid Leukemia By Stage

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Acute Myeloid Leukemia Assessment by Route of Administration

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical

Acute Myeloid Leukemia Assessment by Molecule Type

- Recombinant fusion proteins

- Small molecule

- Monoclonal antibody

- Peptide

- Polymer

- Gene therapy

Download sample pages to get an in-depth assessment of the emerging Acute Myeloid Leukemia therapies and key Acute Myeloid Leukemia companies [https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. Acute Myeloid Leukemia Current Treatment Patterns

4. Acute Myeloid Leukemia - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Acute Myeloid Leukemia Late-Stage Products (Phase-III)

7. Acute Myeloid Leukemia Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acute Myeloid Leukemia Discontinued Products

13. Acute Myeloid Leukemia Product Profiles

14. Acute Myeloid Leukemia Key Companies

15. Acute Myeloid Leukemia Key Products

16. Dormant and Discontinued Products

17. Acute Myeloid Leukemia Unmet Needs

18. Acute Myeloid Leukemia Future Perspectives

19. Acute Myeloid Leukemia Analyst Review

20. Appendix

21. Report Methodology

Request the sample PDF to get detailed insights about the Acute Myeloid Leukemia pipeline reports offerings [https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-myeloid-leukemia-pipeline-2025-innovative-clinical-developments-by-110-global-leaders-delveinsight-featuring-sellas-life-sciences-stemline-therapeutics-wugen-schrodinger-mei-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.